These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 24570071)
1. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071 [TBL] [Abstract][Full Text] [Related]
2. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Irazabal MV; Torres VE; Hogan MC; Glockner J; King BF; Ofstie TG; Krasa HB; Ouyang J; Czerwiec FS Kidney Int; 2011 Aug; 80(3):295-301. PubMed ID: 21544064 [TBL] [Abstract][Full Text] [Related]
3. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953 [TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426 [TBL] [Abstract][Full Text] [Related]
5. Review of tolvaptan for autosomal dominant polycystic kidney disease. Baur BP; Meaney CJ Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579 [TBL] [Abstract][Full Text] [Related]
6. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711 [TBL] [Abstract][Full Text] [Related]
7. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS; Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543 [TBL] [Abstract][Full Text] [Related]
8. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084 [TBL] [Abstract][Full Text] [Related]
10. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. Bennett H; McEwan P; Hamilton K; O'Reilly K BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270 [TBL] [Abstract][Full Text] [Related]
11. Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. Boertien WE; Meijer E; de Jong PE; Bakker SJ; Czerwiec FS; Struck J; Oberdhan D; Shoaf SE; Krasa HB; Gansevoort RT Kidney Int; 2013 Dec; 84(6):1278-86. PubMed ID: 23903369 [TBL] [Abstract][Full Text] [Related]
12. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745 [TBL] [Abstract][Full Text] [Related]